Matthew R LeBlanc1, Rachel Hirschey2, Ashley Leak Bryant2, Thomas W LeBlanc3, Sophia K Smith4. 1. Duke University School of Nursing, 307 Trent Drive, Durham, NC, 27710, USA. matthew.leblanc@duke.edu. 2. University of North Carolina Chapel Hill School of Nursing, Campus Box #7460, Carrington Hall, Chapel Hill, NC, 27599, USA. 3. Duke University School of Medicine, 8 Searle Center Drive, Durham, NC, 27710, USA. 4. Duke University School of Nursing, 307 Trent Drive, Durham, NC, 27710, USA.
Abstract
PURPOSE: Patients with relapsed and/or refractory multiple myeloma (RRMM) are living longer due in part to changing treatment patterns. It is important to understand how changing treatment patterns affect patients' lives beyond extending survival. Research suggests that direct patient report is the best way to capture information on how patients feel and function in response to their disease and its treatment. Therefore, the purpose of this review is to summarize evidence of patients' experience collected through patient-reported outcomes (PRO) in RRMM patients, and to explore PRO reporting quality. METHODS: We conducted a systematic search to identify manuscripts reporting PROs in RRMM and summarized available evidence. We assessed PRO reporting quality using the Consolidated Standards of Reporting Trials (CONSORT) PRO Extension checklist. RESULTS: Our search resulted in 30 manuscripts. Thirteen unique PRO measures were used to assess 18 distinct PRO domains. Pain, fatigue, and emotional function were commonly assessed domains though reporting formats limited our ability to understand prevalence and severity of PRO challenges in RRMM. Evaluation of PRO reporting quality revealed significant reporting deficiencies. Several reporting criteria were included in less than 25% of manuscripts. CONCLUSIONS: Existing evidence provides a limited window for understanding the patient experience of RRMM and is further limited by suboptimal reporting quality. Observational studies are needed to describe prevalence, severity and patterns of PROs in RRMM overtime. Future studies that incorporate PROs would benefit from following existing guidelines to ensure that study evidence and conclusions can be fully assessed by readers, clinicians and policy makers.
PURPOSE:Patients with relapsed and/or refractory multiple myeloma (RRMM) are living longer due in part to changing treatment patterns. It is important to understand how changing treatment patterns affect patients' lives beyond extending survival. Research suggests that direct patient report is the best way to capture information on how patients feel and function in response to their disease and its treatment. Therefore, the purpose of this review is to summarize evidence of patients' experience collected through patient-reported outcomes (PRO) in RRMM patients, and to explore PRO reporting quality. METHODS: We conducted a systematic search to identify manuscripts reporting PROs in RRMM and summarized available evidence. We assessed PRO reporting quality using the Consolidated Standards of Reporting Trials (CONSORT) PRO Extension checklist. RESULTS: Our search resulted in 30 manuscripts. Thirteen unique PRO measures were used to assess 18 distinct PRO domains. Pain, fatigue, and emotional function were commonly assessed domains though reporting formats limited our ability to understand prevalence and severity of PRO challenges in RRMM. Evaluation of PRO reporting quality revealed significant reporting deficiencies. Several reporting criteria were included in less than 25% of manuscripts. CONCLUSIONS: Existing evidence provides a limited window for understanding the patient experience of RRMM and is further limited by suboptimal reporting quality. Observational studies are needed to describe prevalence, severity and patterns of PROs in RRMM overtime. Future studies that incorporate PROs would benefit from following existing guidelines to ensure that study evidence and conclusions can be fully assessed by readers, clinicians and policy makers.
Authors: Erin E Kent; Anita Ambs; Sandra A Mitchell; Steven B Clauser; Ashley Wilder Smith; Ron D Hays Journal: Cancer Date: 2014-11-04 Impact factor: 6.860
Authors: Benjamin D Smith; Grace L Smith; Arti Hurria; Gabriel N Hortobagyi; Thomas A Buchholz Journal: J Clin Oncol Date: 2009-04-29 Impact factor: 44.544
Authors: Shaji K Kumar; S Vincent Rajkumar; Angela Dispenzieri; Martha Q Lacy; Suzanne R Hayman; Francis K Buadi; Steven R Zeldenrust; David Dingli; Stephen J Russell; John A Lust; Philip R Greipp; Robert A Kyle; Morie A Gertz Journal: Blood Date: 2007-11-01 Impact factor: 22.113
Authors: Matthew R LeBlanc; Ashley Leak Bryant; Thomas W LeBlanc; Qing Yang; Emily Sellars; Cristiana Costa Chase; Sophia K Smith Journal: Support Care Cancer Date: 2022-03-09 Impact factor: 3.359
Authors: Tobias Dechow; Ali Aldaoud; Timo Behlendorf; Wolfgang Knauf; Henning Eschenburg; Matthias Groschek; Richard Hansen; Ulrike Söling; Sina Grebhardt; Hans Ulrich Siebenbach; Corinne Vannier; Karin Potthoff Journal: Eur J Haematol Date: 2021-11-15 Impact factor: 3.674
Authors: Alessandra Larocca; Xavier Leleu; Cyrille Touzeau; Joan Bladé; Agne Paner; María-Victoria Mateos; Michele Cavo; Christopher Maisel; Adrían Alegre; Albert Oriol; Anastasios Raptis; Paula Rodriguez-Otero; Amitabha Mazumder; Jacob Laubach; Omar Nadeem; Anna Sandberg; Marie Orre; Anna Torrång; Nicolaas A Bakker; Paul G Richardson Journal: Br J Haematol Date: 2021-10-21 Impact factor: 8.615
Authors: Christopher E Jensen; Sanah N Vohra; Kirsten A Nyrop; Allison M Deal; Matthew R LeBlanc; Shakira J Grant; Hyman B Muss; Eben I Lichtman; Samuel M Rubinstein; William A Wood; Nicholas J Mangieri; Lee Jamison; Sascha A Tuchman Journal: Oncologist Date: 2022-08-05 Impact factor: 5.837
Authors: Lydia Brock; Brooke Hightower; Ty Moore; Danya Nees; Benjamin Heigle; Samuel Shepard; Micah Kee; Ryan Ottwell; Micah Hartwell; Matt Vassar Journal: Arthrosc Sports Med Rehabil Date: 2022-07-15
Authors: Rebecca Mercieca-Bebber; Olalekan Lee Aiyegbusi; Madeleine T King; Michael Brundage; Claire Snyder; Melanie Calvert Journal: Qual Life Res Date: 2022-03-26 Impact factor: 3.440
Authors: Matthew Lyall; Rebecca Crawford; Timothy Bell; Carla Mamolo; Alexander Neuhof; Courtney Levy; Anne Heyes Journal: JMIR Cancer Date: 2022-09-22